DGX's Q2 results may reflect growth across physician, hospital and consumer channels as AI tools and advanced diagnostics gain traction.

zacks.com - 2026-07-14 11:01:33

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-07-10 10:41:17

American Oncology Network (AON) and other community oncology providers launching now as part of a pilot program that provides access to Haystack MRD SECAUCUS, N.J., July 8, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced it is integrating its Haystack MRD® ctDNA test and Comprehensive Genomic Profiling services for solid tumor cancers within OncoEMR®, an electronic health record (EHR) from Flatiron Health, via a pilot program with American Oncology Network (AON) and other community oncology providers.

prnewswire.com - 2026-07-08 08:52:00

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-07-06 10:51:09

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

zacks.com - 2026-07-02 10:16:05

Quest Diagnostics gains NYSDOH approval for Haystack MRD, expanding the cancer test to all 50 states and strengthening its oncology reach.

zacks.com - 2026-06-25 11:31:06

On June 24, 2026, Quest Diagnostics Inc (DGX) shares rose 3.0% today, currently trading at $203.11. This performance places the stock well within its 52-week ra

gurufocus.com - 2026-06-24 18:12:00

Achieving the rigorous laboratory standard broadens access for providers and patients in New York; applies to use of Haystack MRD for patients with solid tumor cancers SECAUCUS, N.J., June 24, 2026 /PRNewswire/ -- Quest Diagnostics® (NYSE: DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has approved the company's Haystack MRD® test, a circulating tumor DNA (ctDNA) liquid biopsy test, for use in identifying residual or recurring disease in patients with a range of solid tumor cancers.

prnewswire.com - 2026-06-24 08:52:00

DGX gains from Advanced Diagnostics, physician and consumer testing growth, plus AI-driven efficiency efforts, even as debt and policy risks linger.

zacks.com - 2026-06-23 10:01:23

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-06-19 10:51:07

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-06-18 10:41:20

Published in Nature Communications, the new study finds that nearly 70% of a common bacterial strain that causes urinary tract infections, pneumonia and wound infections was non-susceptible to the three most used oral antibiotics SECAUCUS, N.J., June 18, 2026 /PRNewswire/ -- A common bacterial strain that lives naturally in people's guts can cause a dangerous or deadly infection for some, especially when it becomes multidrug-resistant and causes chronic urinary-tract infections (UTIs) in elderly women.

prnewswire.com - 2026-06-18 08:57:00

SECAUCUS, N.J., June 17, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its second quarter 2026 financial results on Thursday, July 23, 2026, before the market opens.

prnewswire.com - 2026-06-17 09:00:00

SECAUCUS, N.J., June 16, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today unveiled its 2025 Corporate Responsibility Report.

prnewswire.com - 2026-06-16 09:00:00

An aging population and rising telehealth and AI adoption boost demand in the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, LFST and AVAH stand to benefit.

zacks.com - 2026-06-09 11:41:06

Oura Ring's IPO looks like Peloton in 2020 - great product, dangerous price. Ten public wellness stocks own the real trade.

investorplace.com - 2026-06-05 00:00:00

Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

zacks.com - 2026-05-29 13:01:10

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-05-28 10:40:40

Here is how Quest Diagnostics (DGX) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

zacks.com - 2026-05-26 10:40:35

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?

zacks.com - 2026-05-21 12:31:32

SECAUCUS, N.J., May 19, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on July 22, 2026 to shareholders of record of Quest Diagnostics common stock on July 8, 2026.

prnewswire.com - 2026-05-19 16:37:00

Quest Diagnostics gains from DIS growth, advanced diagnostics uptake and AI-driven efficiencies, though debt levels and healthcare reimbursement risks remain concerns.

zacks.com - 2026-05-19 10:30:40

Almost half of S&P 500 stocks are down for the year, but a bunch show signs they are reviving. Our screen spotlights the most promising.

barrons.com - 2026-05-14 14:22:00

Guidance upgrades are generally among the most bullish announcements a company can make, signaling that the outlook is even better than previously expected.

zacks.com - 2026-05-07 19:45:11

Quest Diagnostics delivered strong Q1 results with 9.2% revenue growth and 13% EPS growth, driving management to raise 2026 guidance. DGX's growth is fueled by advanced diagnostics, robust consumer and hospital channels, and efficiency gains from AI and automation. Key risks include margin pressure from lower-priced partnership volumes and potential Medicare reimbursement cuts under PAMA.

seekingalpha.com - 2026-05-07 15:40:08

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com - 2026-05-06 10:41:30

SECAUCUS, N.J., April 27, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX) (the "Company"), a leader in diagnostic information services, today announced the pricing of a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036 (the "Notes") under Quest Diagnostics' shelf registration statement.

prnewswire.com - 2026-04-27 16:10:00

AEGON ASSET MANAGEMENT UK Plc cut its holdings in Quest Diagnostics Incorporated (NYSE: DGX) by 23.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 90,605 shares of the medical research company's stock after selling 27,786

defenseworld.net - 2026-04-26 03:09:00

Quest Diagnostics delivered Q1 2026 revenue of $2.9 billion (+9.2% YoY) and EPS of $2.24 (+15.5% YoY), but shares dipped post-earnings. DGX maintains a strong core business with high barriers to entry, steady but unspectacular growth, and industry-leading market access. Forward P/E is ~19x and P/S

seekingalpha.com - 2026-04-24 10:53:49

Cwm LLC lessened its position in Quest Diagnostics Incorporated (NYSE: DGX) by 28.4% in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 18,950 shares of the medical research company's stock after selling 7,532 shares during the quarter. Cwm LLC's holdings in Quest

defenseworld.net - 2026-04-24 03:46:53

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com - 2026-04-22 10:51:20

Quest Diagnostics Incorporated (NYSE:DGX) on Tuesday reported upbeat earnings for the first quarter on Tuesday.

benzinga.com - 2026-04-22 10:27:33

On April 21, 2026, Quest Diagnostics Inc (DGX) shares rose 4.5% to a current price of $205.04. This move is part of a broader uptrend, with the stock experienci

gurufocus.com - 2026-04-21 17:53:00

Quest Diagnostics Incorporated (DGX) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-04-21 11:20:38

DGX posts Q1 2026 earnings and revenue beat, with adjusted EPS up 13% and shares rising in pre-market trading.

zacks.com - 2026-04-21 09:56:27

Quest Diagnostics (DGX) came out with quarterly earnings of $2.5 per share, beating the Zacks Consensus Estimate of $2.37 per share. This compares to earnings of $2.21 per share a year ago.

zacks.com - 2026-04-21 08:56:12

Quest Diagnostics on Tuesday raised its forecast for 2026 profit and revenue after posting first-quarter results above Wall Street ​estimates, citing resilient demand for routine diagnostic testing.

reuters.com - 2026-04-21 07:42:40

First quarter revenues of $2.90 billion, up 9.2% from 2025, with 9.0% organic revenue growth First quarter reported diluted earnings per share ("EPS") of $2.24, up 15.5% from 2025; and adjusted diluted EPS of $2.50, up 13.1% from 2025 Full year 2026 reported diluted EPS now expected to be between $9.58 and $9.78; and adjusted diluted EPS is expected to be between $10.63 and $10.83 SECAUCUS, N.J., April 21, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2026.

prnewswire.com - 2026-04-21 06:47:00

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com - 2026-04-20 10:42:59

Fourteen City of Hope sites across the U.S. participating in research using the Haystack MRD ctDNA Test in patients with breast, colorectal, ovarian, and prostate cancer SECAUCUS, N.J. and LOS ANGELES, April 16, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, is implementing Haystack MRD®, a highly accurate circulating-tumor DNA (ctDNA) minimal residual disease (MRD) test, for clinical trial participants with solid tumor cancers to help guide disease management for patients being treated for breast, colorectal, ovarian and prostate cancer.

prnewswire.com - 2026-04-16 09:00:00

DGX heads into Q1 earnings with steady growth expectations, but estimate cuts and a negative ESP could temper the outlook.

zacks.com - 2026-04-15 10:21:10